ArticleCureus2025
Compliance With Parathyroid Hormone Analog Medications at a Single Osteoporosis Treatment Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research trends and hotspots in osteoporosis associated with gas molecules and related factors: a bibliometric analysis.Medical gas research · 2026Article
- Reply to Bae, I.-S. Comment on "Lee et al. Conservative Treatment with Teriparatide Versus Vertebroplasty for Acute Osteoporotic Vertebral Compression Fractures: A Meta-Analysis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Osteoporosis is the most common metabolic bone disease and is more common in female patients and the elderly. The costs associated with osteoporotic fractures present a significant burden on the healthcare system. While effective pharmacologic therapy exists, treatment initiation and compliance remain suboptimal, leading to increased morbidity. This study evaluated compliance with parathyroid hormone analogs and identified reasons for non-compliance. Methods This was a retrospective study of patients prescribed parathyroid hormone analogs from a single osteoporosis clinic from 2017 to 2022. Of the 100 patients included, 42 were prescribed teriparatide and 58 were prescribed abaloparatide. The primary outcomes of interest were continued compliance with medication therapy and reasons for non-compliance. The secondary outcome of interest was fracture rate. Univariate analyses were performed to identify differences between the two groups, and a Kaplan-Meier curve was generated to show overall compliance. Results The average treatment duration was 15.5 months (95% CI: 13.5-17.4 months); 54 (54%) patients completed the full 24-month medication course. Abaloparatide patients had higher rates of non-compliance than teriparatide patients (33 (56.9%) vs. 13 (31.0%); p=0.018) and had a significantly shorter time to non-compliance (4.1 ± 4.6 vs. 8.8 ± 6.4 months; p=0.027). There was a significant difference in reason for non-compliance between early (≤3 months) and late non-compliant patients (p=0.001). About 19 (79.2%) patients were non-compliant early because of side effects, while 10 (45.5%) patients were non-compliant late because of financial reasons. There were no differences in fracture rates between the two groups. Conclusion More than half of the patients in this study completed the full two-year course of treatment, and the average duration of treatment was over 15 months. The overall fracture rate during and after treatment was low. Financial concerns and side effects were the most common reasons for non-compliance. An additional study would be needed to evaluate methods for improving patient compliance with parathyroid hormone analogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.